Department of Gastroenterology and Transplant Hepatology, Faculty of Medicine, Liver Transplant Institute, Inonu University, Malatya, Turkey.
Faculty of Medicine, HCC Translational Research Unit, Liver Transplant Institute, Inonu University, Malatya, Turkey.
J Gastrointest Cancer. 2021 Dec;52(4):1206-1210. doi: 10.1007/s12029-021-00745-4. Epub 2021 Nov 11.
Hepatitis B virus (HBV) is the one of most common causes of the hepatocellular carcinoma (HCC), especially in eastern world. The aim of this review is to try to understand the relationship between HBV and HCC and to reveal the role of prevention and treatment of HBV infection in reducing the incidence of HCC. Strategies to prevent HCC due to HBV can be classified into three categories. These are primary, secondary, and tertiary preventions. Hepatitis B vaccine is now in the most vital position in preventing HBV-associated HCC. In patients with chronic hepatitis B infection, suppressing viral load with potent antivirals such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV) prevents the development of HCC and improves prognosis by reducing recurrence after HCC treatments. There is currently no clear consensus on which of these drugs should be preferred. Although data on tenofovir alafenamide (TAF) are scarce, available data with TDF suggest that TAF therapy will also be a strong actor for HCC.
乙型肝炎病毒 (HBV) 是肝细胞癌 (HCC) 最常见的病因之一，尤其在东亚地区。本综述的目的是试图了解 HBV 与 HCC 的关系，并揭示预防和治疗 HBV 感染在降低 HCC 发病率方面的作用。预防乙型肝炎病毒引起的 HCC 的策略可分为三类。这些是一级、二级和三级预防。乙型肝炎疫苗现在在预防乙型肝炎病毒相关性 HCC 中处于最重要的地位。在慢性乙型肝炎感染患者中，使用替诺福韦酯 (TDF) 和恩替卡韦 (ETV) 等强效抗病毒药物抑制病毒载量可通过降低 HCC 治疗后复发来预防 HCC 的发生并改善预后。目前尚无明确共识，应首选哪种药物。虽然替诺福韦艾拉酚胺 (TAF) 的数据有限，但 TDF 的现有数据表明，TAF 治疗也将是 HCC 的有力治疗药物。
